{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T13:31:45Z","timestamp":1765632705125,"version":"3.48.0"},"reference-count":172,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1053\/j.seminhematol.2025.06.001","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T12:09:12Z","timestamp":1749557352000},"page":"141-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The genomic landscape of acute myeloid leukemia: Redefining classifications, ontogeny, and therapeutic strategies"],"prefix":"10.1053","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3927-1022","authenticated-orcid":false,"given":"Nicolas","family":"Duployez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Preudhomme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7382","key":"10.1053\/j.seminhematol.2025.06.001_bib0001","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.001_bib0002","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"key":"10.1053\/j.seminhematol.2025.06.001_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12475","article-title":"Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia","volume":"7","author":"Hirsch","year":"2016","journal-title":"Nat Commun"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.001_bib0004","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.06.001_bib0005","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.001_bib0006","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.001_bib0007","first-page":"109","article-title":"Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia","volume":"16","author":"Rowley","year":"1973","journal-title":"Ann Genet"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.06.001_bib0008","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ijc.2910200608","article-title":"Further evidence for a non-random chromosomal abnormality in acute promyelocytic leukemia","volume":"20","author":"Rowley","year":"1977","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.06.001_bib0009","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM198309153091103","article-title":"Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association","volume":"309","author":"Le Beau","year":"1983","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.06.001_bib0010","doi-asserted-by":"crossref","first-page":"9358","DOI":"10.1073\/pnas.87.23.9358","article-title":"Mapping chromosome band 11q23 in human acute leukemia with biotinylated probes: identification of 11q23 translocation breakpoints with a yeast artificial chromosome","volume":"87","author":"Rowley","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6293","key":"10.1053\/j.seminhematol.2025.06.001_bib0011","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/347558a0","article-title":"The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus","volume":"347","author":"de Th\u00e9","year":"1990","journal-title":"Nature"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.001_bib0012","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood.V80.7.1825.1825","article-title":"Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1\/ETO, with similarity to Drosophila segmentation gene, runt","volume":"80","author":"Erickson","year":"1992","journal-title":"Blood"},{"issue":"5124","key":"10.1053\/j.seminhematol.2025.06.001_bib0013","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1126\/science.8351518","article-title":"Fusion between transcription factor CBF beta\/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia","volume":"261","author":"Liu","year":"1993","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2025.06.001_bib0014","unstructured":"Iida S, Seto M, Yamamoto K, et al. MLLT3 gene on 9p22 involved in t(9;11) leukemia encodes a serine\/proline rich protein homologous to MLLT1 on 19p13. Oncogene. 1993;8(11):3085-3092."},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.001_bib0015","first-page":"1911","article-title":"Internal tandem duplication of the flt3 gene found in acute myeloid leukemia","volume":"10","author":"Nakao","year":"1996","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.001_bib0016","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/85820","article-title":"Dominant-negative mutations of CEBPA, encoding CCAAT\/enhancer binding protein-alpha (C\/EBPalpha), in acute myeloid leukemia","volume":"27","author":"Pabst","year":"2001","journal-title":"Nat Genet"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.001_bib0017","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"GIMEMA Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.001_bib0018","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.06.001_bib0019","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.001_bib0020","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.06.001_bib0021","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.06.001_bib0022","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"7218","key":"10.1053\/j.seminhematol.2025.06.001_bib0023","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nature07485","article-title":"DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome","volume":"456","author":"Ley","year":"2008","journal-title":"Nature"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.06.001_bib0024","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult De novo acute myeloid leukemia","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.06.001_bib0025","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/leu.2013.77","article-title":"A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice","volume":"27","author":"Mupo","year":"2013","journal-title":"Leukemia"},{"issue":"17","key":"10.1053\/j.seminhematol.2025.06.001_bib0026","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1182\/blood-2017-01-760595","article-title":"Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia","volume":"130","author":"Dovey","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.001_bib0027","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.exphem.2013.10.005","article-title":"NPMc+ cooperates with Flt3\/ITD mutations to cause acute leukemia recapitulating human disease","volume":"42","author":"Rau","year":"2014","journal-title":"Exp Hematol"},{"issue":"7834","key":"10.1053\/j.seminhematol.2025.06.001_bib0028","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.001_bib0029","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1182\/blood.2018862383","article-title":"Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML","volume":"134","author":"Garg","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.06.001_bib0030","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1182\/blood.2019003339","article-title":"Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis","volume":"135","author":"Bezerra","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.001_bib0031","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.2024024310","article-title":"Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML","volume":"144","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.001_bib0032","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/blood-2018-03-837781","article-title":"Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia","volume":"132","author":"Itzykson","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.001_bib0033","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/bloodadvances.2024014672","article-title":"Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia","volume":"9","author":"Joudinaud","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.06.001_bib0034","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.06.001_bib0035","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1182\/bloodadvances.2019001349","article-title":"Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results","volume":"4","author":"Gardin","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0036","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","article-title":"Unified classification and risk-stratification in Acute Myeloid Leukemia","volume":"13","author":"Tazi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1053\/j.seminhematol.2025.06.001_bib0037","first-page":"1","article-title":"Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia","author":"Mecklenbrauck","year":"2025","journal-title":"Leukemia"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.06.001_bib0038","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1158\/1078-0432.CCR-22-1622","article-title":"on behalf of UNIHEM, French Network of Pharmacovigilance Centers, ALFA, FILO, and GFM. Therapy-related myeloid neoplasms following PARP inhibitors: real-life experience","volume":"28","author":"Marmouset","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.06.001_bib0039","first-page":"1289","article-title":"Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes","volume":"109","author":"Escure","year":"2024","journal-title":"Haematologica"},{"issue":"7540","key":"10.1053\/j.seminhematol.2025.06.001_bib0040","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.06.001_bib0041","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.06.001_bib0042","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-023-00821-x","article-title":"TP53 mutation variant allele frequency of \u226510% is associated with poor prognosis in therapy-related myeloid neoplasms","volume":"13","author":"Shah","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0044","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-024-01590-1","article-title":"Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients","volume":"17","author":"Halik","year":"2024","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.06.001_bib0045","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"37","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-025-01290-0","article-title":"Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort","volume":"15","author":"Shah","year":"2025","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.001_bib0047","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41375-023-02102-9","article-title":"Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia","volume":"38","author":"Hoffmeister","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0048","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3324\/haematol.2021.280250","article-title":"Analysis of rare driving events in pediatric acute myeloid leukemia","volume":"108","author":"Noort","year":"2023","journal-title":"Haematologica"},{"issue":"20","key":"10.1053\/j.seminhematol.2025.06.001_bib0049","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1182\/bloodadvances.2019000404","article-title":"Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia","volume":"3","author":"Shiba","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.001_bib0050","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41588-023-01640-3","article-title":"A new genomic framework to categorize pediatric acute myeloid leukemia","volume":"56","author":"Umeda","year":"2024","journal-title":"Nat Genet"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.06.001_bib0051","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41375-024-02137-6","article-title":"Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses","volume":"38","author":"Severens","year":"2024","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.001_bib0052","doi-asserted-by":"crossref","unstructured":"Klossowski S, Miao H, Kempinska K, et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Invest. 130(2):981-997. doi:10.1172\/JCI129126","DOI":"10.1172\/JCI129126"},{"issue":"7954","key":"10.1053\/j.seminhematol.2025.06.001_bib0053","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0054","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with Revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.06.001_bib0055","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","author":"Arellano","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.06.001_bib0056","doi-asserted-by":"crossref","first-page":"e935","DOI":"10.1097\/HS9.0000000000000935","article-title":"The MLL\u2013Menin interaction is a therapeutic vulnerability in NUP98-rearranged AML","volume":"7","author":"Rasouli","year":"2023","journal-title":"HemaSphere"},{"issue":"24","key":"10.1053\/j.seminhematol.2025.06.001_bib0057","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1056\/NEJMc2404110","article-title":"Response and resistance to Menin inhibitor in UBTF-Tandem duplication AML","volume":"390","author":"Tiong","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.001_bib0058","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2023021359","article-title":"Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors","volume":"143","author":"Barajas","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0059","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1097\/HS9.0000000000000031","article-title":"Molecular profiling defines distinct prognostic subgroups in childhood AML: A report from the French ELAM02 Study Group","volume":"2","author":"Marceau-Renaut","year":"2018","journal-title":"HemaSphere"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.001_bib0060","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/2643-3230.BCD-21-0160","article-title":"Integrated genomic analysis identifies UBTF tandem duplications as a recurrent lesion in pediatric acute myeloid leukemia","volume":"3","author":"Umeda","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.06.001_bib0061","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/s41375-023-01906-z","article-title":"UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia","volume":"37","author":"Duployez","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.001_bib0062","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/leu.2012.249","article-title":"Analysis of NUP98\/NSD1 translocations in adult AML and MDS patients","volume":"27","author":"Thol","year":"2013","journal-title":"Leukemia"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.06.001_bib0063","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1182\/blood-2014-04-570929","article-title":"NUP98\/NSD1 and FLT3\/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report","volume":"124","author":"Ostronoff","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.06.001_bib0064","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/s41375-024-02312-9","article-title":"Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations","volume":"38","author":"Miao","year":"2024","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.001_bib0065","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2021015328","article-title":"Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study","volume":"140","author":"Duployez","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.06.001_bib0066","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/s41375-024-02180-3","article-title":"Clinical impact of genetic alterations including germline DDX41 mutations in MDS\/low-blast count AML patients treated with azacitidine-based regimens","volume":"38","author":"S\u00e9bert","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0067","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-023-00858-y","article-title":"Study Alliance Leukemia (SAL). UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome","volume":"13","author":"Georgi","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2025.06.001_bib0068","article-title":"Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients","author":"Jahn","year":"2023","journal-title":"Leukemia"},{"issue":"13","key":"10.1053\/j.seminhematol.2025.06.001_bib0069","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood.2022017715","article-title":"DDX41-associated susceptibility to myeloid neoplasms","volume":"141","author":"Makishima","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.06.001_bib0070","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1182\/blood.2020005524","article-title":"A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia","volume":"137","author":"Fenwarth","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.001_bib0071","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.2021011103","article-title":"Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy","volume":"138","author":"Itzykson","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0072","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1002\/ajh.25328","article-title":"Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hauts-de-France AML observatory","volume":"94","author":"Renaud","year":"2019","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.06.001_bib0073","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.2019003471","article-title":"Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia","volume":"135","author":"Fournier","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0074","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.001_bib0075","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/ng.3756","article-title":"Precision oncology for acute myeloid leukemia using a knowledge bank approach","volume":"49","author":"Gerstung","year":"2017","journal-title":"Nat Genet"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.06.001_bib0076","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.001_bib0077","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.06.001_bib0078","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/cdd.2017.82","article-title":"BCL-2 family: integrating stress responses at the ER to control cell demise","volume":"24","author":"Pih\u00e1n","year":"2017","journal-title":"Cell Death Differ"},{"issue":"24","key":"10.1053\/j.seminhematol.2025.06.001_bib0079","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with Venetoclax and Azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.06.001_bib0080","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/bloodadvances.2024014900","article-title":"Final analysis of the phase 1b chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT)","volume":"9","author":"Chua","year":"2025","journal-title":"Blood Adv"},{"issue":"20","key":"10.1053\/j.seminhematol.2025.06.001_bib0081","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood.2020010167","article-title":"Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias","volume":"137","author":"Thijssen","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.001_bib0082","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.06.001_bib0083","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.06.001_bib0084","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.06.001_bib0085","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ajh.25146","article-title":"Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1053\/j.seminhematol.2025.06.001_bib0086","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","article-title":"FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation","volume":"114","author":"Yoshimoto","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.06.001_bib0087","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat Cancer"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.001_bib0088","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1038\/bcj.2012.5","article-title":"Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies","volume":"2","author":"Kasper","year":"2012","journal-title":"Blood Cancer J"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.06.001_bib0089","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of bcl-2 synergistically enhances the antileukemic activity of Midostaurin and Gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia","volume":"25","author":"Ma","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.06.001_bib0090","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Singh Mali","year":"2021","journal-title":"Haematologica"},{"issue":"30","key":"10.1053\/j.seminhematol.2025.06.001_bib0091","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): A phase ib dose-escalation study of venetoclax combined with modified intensive Chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.06.001_bib0092","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","article-title":"Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax","volume":"8","author":"Bataller","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.06.001_bib0093","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41408-021-00541-0","article-title":"ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine","volume":"11","author":"Rahmani","year":"2021","journal-title":"Blood Cancer J"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.06.001_bib0094","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood.2023020649","article-title":"Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia","volume":"142","author":"Senapati","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.001_bib0095","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.27070","article-title":"Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants","author":"Bataller","year":"2023","journal-title":"Am J Hematol"},{"issue":"26","key":"10.1053\/j.seminhematol.2025.06.001_bib0096","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2024026925","article-title":"Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML","volume":"144","author":"Lachowiez","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.001_bib0097","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.06.001_bib0098","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood.V90.11.4532","article-title":"Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study","volume":"90","author":"Mr\u00f3zek","year":"1997","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.06.001_bib0099","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/pbc.23274","article-title":"MLL gene rearrangements in infant leukemia vary with age at diagnosis and selected demographic factors: a Children\u2019s Oncology Group (COG) study","volume":"58","author":"Sam","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.001_bib0100","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2003-02-0434","article-title":"AML with 11q23\/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases","volume":"102","author":"Schoch","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.001_bib0101","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/sj.leu.2404233","article-title":"A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare \u2018poor prognosis\u2019 myeloid malignancies","volume":"20","author":"Slovak","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.06.001_bib0102","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/leu.2008.388","article-title":"AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features","volume":"23","author":"Haferlach","year":"2009","journal-title":"Leukemia"},{"issue":"24","key":"10.1053\/j.seminhematol.2025.06.001_bib0103","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.2010.29.2771","article-title":"Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)\/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia","volume":"28","author":"Lugthart","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.001_bib0104","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/bloodadvances.2018015594","article-title":"BCR-ABL+ acute myeloid leukemia: are we always dealing with a high-risk disease?","volume":"2","author":"Neuendorff","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/leu.2012.230","article-title":"A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98\u2013NSD1 fusion gene","volume":"27","author":"Fasan","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.001_bib0106","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3324\/haematol.2019.236745","article-title":"The clinical and biological characteristics of NUP98-KDM5A pediatric acute myeloid leukemia","volume":"106","author":"Noort","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.001_bib0107","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ng.3772","article-title":"Pediatric non-down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes","volume":"49","author":"de Rooij","year":"2017","journal-title":"Nat Genet"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.001_bib0108","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1182\/blood.V78.3.748.748","article-title":"The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study","volume":"78","author":"Carroll","year":"1991","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.06.001_bib0109","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2012.10.007","article-title":"An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia","volume":"22","author":"Gruber","year":"2012","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.06.001_bib0110","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.3324\/haematol.2012.082149","article-title":"Acute myeloid leukemia with translocation t(3;5): new molecular insights","volume":"98","author":"Dum\u00e9zy","year":"2013","journal-title":"Haematologica"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.06.001_bib0111","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.leukres.2012.07.008","article-title":"PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients","volume":"36","author":"Borel","year":"2012","journal-title":"Leuk Res"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.06.001_bib0112","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood-2018-05-849059","article-title":"Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group","volume":"132","author":"Noort","year":"2018","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2025.06.001_bib0113","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood-2016-03-703868","article-title":"RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature","volume":"127","author":"Lavall\u00e9e","year":"2016","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.06.001_bib0114","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2025.06.001_bib0115","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1182\/blood-2011-01-328096","article-title":"Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3\/ITD knockin mice","volume":"118","author":"Li","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.001_bib0116","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/gcc.22210","article-title":"Analysis for loss of heterozygosity on chromosome arm 13q by STR analysis or SNP sequencing can replace analysis of FLT3 -ITD to detect patients with prognostically adverse AML: 13q LOH analysis can replace for FLT3- ITD Analysis","volume":"53","author":"Schnittger","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0117","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2013-01-479188","article-title":"Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia","volume":"122","author":"Kr\u00f6nke","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.06.001_bib0118","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2006-04-015826","article-title":"FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia","volume":"110","author":"Mead","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.001_bib0119","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.06.001_bib0120","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.001_bib0121","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2643-3230.BCD-20-0143","article-title":"Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus type II FLT3 inhibitors","volume":"2","author":"Alotaibi","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.06.001_bib0122","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/leu.2013.179","article-title":"Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies","volume":"27","author":"G\u00f3mez-Segu\u00ed","year":"2013","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.001_bib0123","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-024-02429-x","article-title":"Non canonical c-CBL mutations define a specific phenotype of myeloid neoplasia","author":"Guarnera","year":"2025","journal-title":"Leukemia"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.001_bib0124","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1038\/s41375-018-0147-4","article-title":"NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome","volume":"32","author":"Eisfeld","year":"2018","journal-title":"Leukemia"},{"issue":"16","key":"10.1053\/j.seminhematol.2025.06.001_bib0125","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/bloodadvances.2023010156","article-title":"Genomic landscape of TP53-mutated myeloid malignancies","volume":"7","author":"Abel","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.06.001_bib0126","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.2010.30.7926","article-title":"RUNX1 Mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group","volume":"29","author":"Gaidzik","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.06.001_bib0127","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/leu.2016.126","article-title":"RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features","volume":"30","author":"Gaidzik","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0128","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood.2019000937","article-title":"Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA)","volume":"136","author":"Brown","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.06.001_bib0129","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood.2022017874","article-title":"Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions","volume":"141","author":"Ryland","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.001_bib0130","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41375-024-02140-x","article-title":"Prognostic impact of CEBPA mutational subgroups in adult AML","volume":"38","author":"Georgi","year":"2024","journal-title":"Leukemia"},{"issue":"13","key":"10.1053\/j.seminhematol.2025.06.001_bib0131","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood.2020009652","article-title":"CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children\u2019s Oncology Group","volume":"138","author":"Tarlock","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.001_bib0132","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.06.007","article-title":"Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with down syndrome","volume":"36","author":"Labuhn","year":"2019","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.06.001_bib0133","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.3324\/haematol.2014.104406","article-title":"ETV6 mutation in a cohort of 970 patients with hematologic malignancies","volume":"99","author":"Wang","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.06.001_bib0134","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng.3177","article-title":"Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy","volume":"47","author":"Zhang","year":"2015","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2025.06.001_bib0135","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.20027","article-title":"Study Alliance Leukemia (SAL). The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML","author":"Stasik","year":"2025","journal-title":"Br J Haematol"},{"issue":"25","key":"10.1053\/j.seminhematol.2025.06.001_bib0136","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1182\/blood-2009-12-259390","article-title":"WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system","volume":"115","author":"Hou","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.06.001_bib0137","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1200\/JCO.2009.23.0342","article-title":"Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia","volume":"28","author":"Damm","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.06.001_bib0138","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1182\/blood-2008-10-183392","article-title":"Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group","volume":"113","author":"Gaidzik","year":"2009","journal-title":"Blood"},{"issue":"33","key":"10.1053\/j.seminhematol.2025.06.001_bib0139","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1200\/JCO.2008.16.0333","article-title":"Mutation of the Wilms\u2019 tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party","volume":"26","author":"Virappane","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.001_bib0140","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood-2018-03-837468","article-title":"Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis","volume":"132","author":"Pronier","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-024-01066-y","article-title":"The landscape of NUP98 rearrangements clinical characteristics and treatment response from 1491 acute leukemia patients","volume":"14","author":"Tian","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0142","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/s41467-024-46134-w","article-title":"Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting","volume":"15","author":"Kubota","year":"2024","journal-title":"Nat Commun"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.06.001_bib0143","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.001_bib0144","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"issue":"13","key":"10.1053\/j.seminhematol.2025.06.001_bib0145","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0146","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-024-01607-9","article-title":"Landscape of biallelic DNMT3A mutant myeloid neoplasms","volume":"17","author":"Kawashima","year":"2024","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2025.06.001_bib0147","doi-asserted-by":"crossref","unstructured":"St\u00f6lzel F, Fordham SE, Nandana D, et al. Biallelic TET2 mutations confer sensitivity to 5\u2032-azacitidine in acute myeloid leukemia. JCI Insight. 8(2):e150368. doi:10.1172\/jci.insight.150368","DOI":"10.1172\/jci.insight.150368"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.06.001_bib0148","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3324\/haematol.2014.114157","article-title":"ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group","volume":"100","author":"Paschka","year":"2015","journal-title":"Haematologica"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.06.001_bib0149","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1182\/blood-2014-04-571018","article-title":"Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)\/RUNX1-RUNX1T1 chromosomal translocations","volume":"124","author":"Micol","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.06.001_bib0150","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/leu.2017.18","article-title":"Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group","volume":"31","author":"Jahn","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.06.001_bib0151","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/gcc.22542","article-title":"Usefulness of BCOR gene mutation as a prognostic factor in acute myeloid leukemia with intermediate cytogenetic prognosis","volume":"57","author":"Terada","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.06.001_bib0152","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1182\/blood-2011-07-365320","article-title":"Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype","volume":"118","author":"Grossmann","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.001_bib0153","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-025-06346-6","article-title":"Impact of BCOR\/BCORL1 mutation on outcomes of allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients","author":"Zhou","year":"2025","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.06.001_bib0154","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.3324\/haematol.2019.222323","article-title":"EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia","volume":"105","author":"Stasik","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0155","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41375-019-0497-6","article-title":"Loss of KDM6A confers drug resistance in acute myeloid leukemia","volume":"34","author":"Stief","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/leu.2016.160","article-title":"Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD)","volume":"31","author":"Sun","year":"2017","journal-title":"Leukemia"},{"issue":"20","key":"10.1053\/j.seminhematol.2025.06.001_bib0157","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood.2020010165","article-title":"Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study","volume":"137","author":"Duchmann","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.06.001_bib0158","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.stem.2015.09.017","article-title":"Leukemia-associated cohesin mutants dominantly enforce stem cell programs and impair Human hematopoietic progenitor differentiation","volume":"17","author":"Mazumdar","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1053\/j.seminhematol.2025.06.001_bib0159","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114498","article-title":"STAG2 mutations reshape the cohesin-structured spatial chromatin architecture to drive gene regulation in acute myeloid leukemia","author":"Fischer","year":"2024","journal-title":"Cell Rep"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0160","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41408-023-00790-1","article-title":"Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome","volume":"13","author":"Eckardt","year":"2023","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.06.001_bib0161","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/leu.2008.143","article-title":"Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype","volume":"22","author":"Haferlach","year":"2008","journal-title":"Leukemia"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.06.001_bib0162","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1038\/s41375-023-02030-8","article-title":"Ppm1d truncating mutations promote the development of genotoxic stress-induced AML","volume":"37","author":"Burocziova","year":"2023","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.001_bib0163","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-3683","article-title":"Clonal evolution of PPM1D mutations in the spectrum of myeloid disorders","author":"Fandrei","year":"2025","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1053\/j.seminhematol.2025.06.001_bib0164","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107500","article-title":"Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia","volume":"141","author":"Berton","year":"2024","journal-title":"Leuk Res"},{"issue":"17","key":"10.1053\/j.seminhematol.2025.06.001_bib0165","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1182\/bloodadvances.2021004556","article-title":"Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification","volume":"5","author":"van der Werf","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.001_bib0166","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1038\/s41375-022-01734-7","article-title":"SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase","volume":"36","author":"Huber","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.06.001_bib0167","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood.2021015325","article-title":"Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia","volume":"140","author":"Tanaka","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.06.001_bib0168","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1182\/blood-2005-08-3167","article-title":"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)","volume":"107","author":"Thiede","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.06.001_bib0169","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1182\/blood-2005-05-2164","article-title":"Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations","volume":"106","author":"D\u00f6hner","year":"2005","journal-title":"Blood"},{"issue":"17","key":"10.1053\/j.seminhematol.2025.06.001_bib0170","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood.2019000909","article-title":"Germline DDX41 mutations define a significant entity within adult MDS\/AML patients","volume":"134","author":"S\u00e9bert","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.06.001_bib0171","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2022018221","article-title":"Germ line DDX41 mutations define a unique subtype of myeloid neoplasms","volume":"141","author":"Makishima","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.06.001_bib0172","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.19105","article-title":"Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients","volume":"204","author":"Nanaa","year":"2024","journal-title":"Br J Haematol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T13:29:05Z","timestamp":1765632545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":172,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0037196325000253"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.06.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The genomic landscape of acute myeloid leukemia: Redefining classifications, ontogeny, and therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}